Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis

Monica Tang, Timothy Jay Price, Jeremy Shapiro, Peter Gibbs, Daniel G. Haller, Dirk Arnold, Marc Peeters, Eva Segelov, Amitesh Roy, Niall Tebbutt, Nick Pavlakis, Chris Karapetis, Matthew Burge

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Introduction: Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.

Original languageEnglish
Pages (from-to)339-349
Number of pages11
JournalExpert Review of Anticancer Therapy
Issue number4
Publication statusPublished - 3 Apr 2018


  • adjuvant treatment
  • chemotherapy
  • Colon cancer
  • duration of chemotherapy
  • IDEA collaboration

Cite this